Slow, repetitive transcranial magnetic stimulation was effective for major depression


Question
In patients with major depression, is slow, repetitive transcranial magnetic stimulation (rTMS) effective for relieving depressive symptoms?

Design
2 week randomised, double blind, placebo controlled trial.

Setting
[Psychiatric department of a general hospital]* in Israel.

Patients
70 patients (mean age 59 y, 76% women) who had major depression according to the DSM-IV; were right handed; had normal neurological and general physical examination results; did not have a history of major brain trauma, seizure disorder, or substance abuse; and were not medication resistant. Follow up was 90%.

Intervention
Patients were allocated to rTMS (n = 36) or sham rTMS (n = 34). In rTMS, a magnetic stimulator (Cadwell Inc, Kennewick, Washington, USA) with a 9 cm external diameter circular coil was placed over the right prefrontal area 6 cm anterior to the scalp position at which the motor threshold was determined. In sham rTMS, the stimulation coil was placed perpendicular to the scalp without direct contact. 10 daily sessions were given over 2 weeks.

Main outcome measures
Severity of depression (assessed with the Hamilton Depression Rating Scale [HDRS] and the Montgomery-Asberg Depression Rating Scale [MADRS]) at baseline, after 1 week of treatment, and at 24 hours after the last treatment session.

Main results
More patients in the rTMS group than in the sham-rTMS group had ≥50% reduction in HDRS or MADRS scores (p < 0.05) and had a final HDRS score ≤10 (p<0.02) (table). No serious adverse effects were reported in either group.

Conclusion
In patients with major depression, slow, repetitive transcranial magnetic stimulation led to a reduction in depressive symptoms.

Abstract and commentary also published in Evidence-Based Medicine.

Page 612 of 612

Rapid rTMS is a method of stimulating the cerebral cortex by using magnetic fields generated in an electrical coil. Applied to appropriate brain areas, rTMS can influence cognitive function and perhaps mood in healthy people. The abnormalities in prefrontal perfusion found by functional brain imaging studies in some depressed patients have led to therapeutic trials of rTMS in major depression.

Klein et al found clinically significant antidepressant effects with low frequency rTMS applied to the right prefrontal area. This study has substantial methodological differences from other positive controlled studies of rTMS in regard to the stimuli used, their site of application, and the coil used to deliver them. The level of severity of the patients’ symptoms is not easy to assess. On the one hand, they were inpatients, but, on the other, none were deemed treatment resistant. Such patients would be unusual in an inpatient setting in the UK.

Antidepressant effects of rTMS raise the tantalising prospect that it may be possible to replace electroconvulsive therapy (ECT) with a treatment that does not require anaesthesia or cause fits or cognitive impairment. Unlike most patients treated with ECT, however, patients in this study were not medication resistant, and concomitant medication may have influenced the therapeutic response to rTMS.

More work is required to define the most appropriate stimulus variables and placement for rTMS in the treatment of depression. In addition, a more convincing placebo treatment than sham application needs to be devised. The failure of some studies to replicate specific antidepressant effects of rTMS suggests that this is not a trivial issue. Another important area for study is the duration of therapeutic effect of rTMS. The successful use of ECT in medication resistant patients is unfortunately often followed by high relapse rates and, presumably, similar problems might attend the use of rTMS in such patients.

Philip J Cowen, MD
University of Oxford
Oxford, UK

1 George MS, Lisanby SH, Sackeim HA. Transcranial magnetic stimulation: applications in neuropsychiatry. Arch Gen Psychiatry 1999;56:300–11.
Slow, repetitive transcranial magnetic stimulation was effective for major depression

_Evid Based Mental Health_ 1999 2: 114
doi: 10.1136/ebmh.2.4.114

Updated information and services can be found at:
_http://ebmh.bmj.com/content/2/4/114_

_These include:_

**References**
This article cites 3 articles, 0 of which you can access for free at:
_http://ebmh.bmj.com/content/2/4/114#BIBL_

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Depressive disorder (570)
- Complementary medicine (52)
- Substance dependence (407)
- Epidemiology (1570)
- Therapeutic trials (1)
- Clinical trials (epidemiology) (989)
- Drugs: psychiatry (344)
- Neurology (1070)

**Notes**

To request permissions go to:
_http://group.bmj.com/group/rights-licensing/permissions_

To order reprints go to:
_http://journals.bmj.com/cgi/reprintform_

To subscribe to BMJ go to:
_http://group.bmj.com/subscribe/_)